Phase II Completion and Phase III Prep

• February/June: CS060304 IND approved in China and U.S.

• April: CS0159 completed Phase II trial in the U.S. (NASH).

• May/August: CS060380 IND approved in China and U.S.; Phase I trial started.

• December: Recognized as an Outstanding Enterprise at the 13th China Innovation and Entrepreneurship Competition.

Phase II Trials for CS0159

• January: CS0159 received Fast Track designation (NASH) from FDA.

• March: Named a "Specialized and Innovative SME" by Shanghai Government.

• March: IND approval for NASH in China.

• August: Held launch meeting for Phase II trial in China.

• December: Listed as one of Shanghai's "Top 50 Most Investable Startups 2023".

Phase I Trials for CS0159

• January: NMPA approved IND for CS0159 (PSC).

• September: Phase I dosing completed in the U.S.

• October: NMPA approved IND for CS0159 (PBC).

• December: FDA approved IND for CS0159 (NASH).

• December: First patient dosed (FPI) in China.

First IND Approval

• September: CS0159 received FDA Orphan Drug Designation (ODD) for PSC.

• October: FDA approved IND for CS0159 (PSC).

• December: First patient dosed (FPI) in the U.S.

First IND and Series A Financing

• July: Started IND-enabling studies for CS0159.

• August: Adjusted equity structure and set up ESOP.

Relocation

• April: Zhoupu Site started operations.

• May: Animal facility approved.

Start-up

• March: Kangqiao East Road Site started operations.

Established

December: Cascade was founded.